Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Postprandial Hypoglycaemia After Gastric Bypass
NCT05057819Phase 4Completed
- Sponsor
- Insel Gruppe
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in post-bariatric hypoglycemia (PBH) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Amplitude of change in plasma glucose. Started Dec 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT05057819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057819.